A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
ACADEMIA
A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
The ALS drug development is gaining momentum, but as with Alzheimer’s, researchers should target the early onset stage and preclinical phase of the disease to achieve more effective treatments. So argues Prof. Yuishin Izumi of Tokushima University, a key figure…
To read the full story
Related Article
- A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
August 27, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- A Time for Patience - 2: Will High-Dose Mecobalamin and Tofersen Become First-Line Treatments in ALS?
August 23, 2024
- A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
ACADEMIA
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
- Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
September 3, 2025
- Tohoku University Trial Finds Kidney Benefits for Constipation Drug Lubiprostone
September 3, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…